The Reality of CAR T-cell Therapy: Am I Eligible?

   Chimeric antigen receptor T cell (CAR T-cell) therapy is a form of immunotherapy that is currently being investigated in clinical trials for the treatment of myeloma. Immunotherapy works by using your immune system to fight cancer. In CAR-T-cell treatment, a type of immune cell, known as T cells, are genetically programmed with a chimeric antigen receptor (CAR) protein that enables them to recognise and destroy cancerous myeloma cells in your body.

The FDA approves melphalan flufenamide for patients with relapsed or refractory myeloma

    The U.S. Food and Drug Administration (FDA) has approved melphalan flufenamide (PEPAXTO®), also known as melflufen, in combination with dexamethasone, for the treatment of adult patients with relapsed or refractory myeloma, who have received at least four prior lines of therapy and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one CD38-directed monoclonal antibody.

Job offer – Research Assistant

   Location: Scotland / home based (approx. 10 travel days per year) Contract: 40 hours per week / permanent Salary: £25,000 – £27,000 depending on experience   This Research Assistant post supports the research function of Myeloma Patients Europe (MPE). There are two main elements to the job – supporting communication and dissemination of SISAQOL-IMI and to assist with generating patient centred evidence as part of MPE’s newly established Evidence Generation Unit (EGU). The following…

Generating recommendations for patient- reported outcome (PRO): SISAQOL-IMI

  An international multidisciplinary consortium, guided by the European Organisation for Research and Treatment of Cancer (EORTC), has been convened to generate recommendations to standardize the use, analysis, and interpretation of PRO data in cancer clinical trials. Myeloma Patients Europe (MPE) is one of the partners in this project representing the Workgroup or European Cancer Patient Advocacy Networks (WECAN).

Selinexor receives positive opinion from the EMA for the treatment of refractory myeloma

  The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the conditional approval for selinexor in combination with dexamethasone for the treatment of adult myeloma patients who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, two immunomodulatory agents, and an anti-CD38 monoclonal antibody, and who have demonstrated disease progression on the last therapy.